BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29387987)

  • 21. Robot-assisted supine extraperitoneal retroperitoneal lymph node dissection: a novel approach for template dissection in post-chemotherapy residual mass in non-seminomatous germ cell tumours.
    Pooleri GK; Bijalwan P; Kesavan R; Philip A; Keechilat P
    J Robot Surg; 2019 Feb; 13(1):171-173. PubMed ID: 29728822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Klein EA
    BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.
    Syan-Bhanvadia S; Bazargani ST; Clifford TG; Cai J; Miranda G; Daneshmand S
    Eur Urol; 2017 Nov; 72(5):814-820. PubMed ID: 28325537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
    Heidenreich A; Paffenholz P; Nestler T; Pfister D
    Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings.
    Brown JA; Bihrle R; Foster RS
    Urology; 2008 May; 71(5):911-4. PubMed ID: 18342916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymph node density in retroperitoneal lymph node dissection as a novel marker for predicting recurrence in patients with germ cell testicular cancer: A case-control study and long-term clinical experience of a tertiary referral hospital.
    Sarikaya S; Karsiyakali N; Kaya E; Topuz B; Ebiloglu T; Zor M
    Actas Urol Esp (Engl Ed); 2021; 45(1):30-38. PubMed ID: 33010987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
    Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
    Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
    Peterson M; Beck S; Bihrle R; Einhorn L; Foster R
    BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
    Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
    Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Retroperitoneal lymph node dissection for patients with advanced testicular tumor].
    Takasaki N; Ueda H; Isurugi K
    Hinyokika Kiyo; 1994 Oct; 40(10):957-61. PubMed ID: 7992714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?
    Russell CM; Sharma P; Agarwal G; Fisher JS; Richard GJ; Spiess PE; Pow-Sang JM; Poch MA; Sexton WJ
    Can J Urol; 2016 Feb; 23(1):8127-34. PubMed ID: 26892052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
    Speir RW; Calaway AC; Einhorn LH; Foster RS; Cary C
    Urol Oncol; 2020 Aug; 38(8):687.e19-687.e23. PubMed ID: 32448503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.
    Pietzak EJ; Assel M; Becerra MF; Tennenbaum D; Feldman DR; Bajorin DF; Motzer RJ; Bosl GJ; Carver BS; Sjoberg DD; Sheinfeld J
    Urology; 2018 Aug; 118():114-118. PubMed ID: 29704586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surveillance or lymph node dissection in clinical stage I non-seminomatous germinal testis cancer?
    Pizzocaro G; Zanoni F; Salvioni R; Milani A; Piva L
    Br J Urol; 1985 Dec; 57(6):759-62. PubMed ID: 3002535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retroperitoneal lymph node dissection with concomitant IVC thrombectomy, caval wall resection, and grafting for metastatic NSGCT.
    Hakky T; Kim T; Rodriguez AR; Armstrong P; Mangar D; Spiess PE
    Int Braz J Urol; 2012; 38(1):135; discussion 136. PubMed ID: 22397783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Differences Between Surveillance and Active Treatment After Initial Orchiectomy in Patients With Stage I Mixed Germ Cell Tumors of the Testis: A Propensity Score Matching Analysis.
    Du Y; Liu L; Zou B; Chen Z; Chen Q; Deng R; Yang P
    J Surg Res; 2024 Feb; 294():26-36. PubMed ID: 37857140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Machine Learning Model to Predict the Histology of Retroperitoneal Lymph Node Dissection Specimens.
    Nitta S; Kojima T; Gido M; Nakagawa S; Kakeya H; Kandori S; Kawahara T; Mathis BJ; Kawai K; Negoro H; Nishiyama H
    Anticancer Res; 2024 May; 44(5):2151-2157. PubMed ID: 38677742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
    Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
    Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.